AKAmir Karban

Amir Karban

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Amir Karban has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 November 2006
      • Vol. 145  (11) , 789-92, 864

    [The significance of IL-13 gene +2044G/A mutation in patients with inflammatory bowel disease].

    by Matti Waterman, Amir Karban, Shula Nesher, Batia Weiss, Raanan Shamir, Rami Eliakim

    Inflammatory bowel disease (IBD) is caused by a combination of genetic, immunological and environmental factors. Despite recent advances in the study of IBD pathogenesis, including the discovery of the NOD2/CARD15 mutation in 40% of Crohn's Disease (CD) patients, in most IBD patients no known mutations have yet been discovered. The interleukin (IL)-13 gene is located near the IBD5 locus on chromosome 5q31, known to be in linkage disequilibrium with CD. IL-13 has a role in the pathogenesis of several chronic inflammatory diseases including IBD. The +2044G/A mutation, which encodes an IL-13 protein with glutamine instead of arginine, has been associated with various inflammatory conditions. However, its role in IBD has not been defined. This is a study of the role of the IL-13 gene +2044G/A mutation in the susceptibility to and phenotype of IBD. Two hundred and eighty-five patients with CD and 111 cases of ulcerative colitis (UC) were enrolled in the study. Mutation frequency was determined using restriction fragment length polymorphism study in IBD patients and 178 healthy ethnically matched controls. The mutated allele frequency was determined in various clinical sub-groups of IBD patients. Statistical significance of the differences in allele frequency in CD and UC patients and healthy controls was determined. The +2044G/A allele frequency was similar in CD, UC and healthy controls (23.3%, 19.4%, 19.6%, respectively, p = 0.294). There was no significant association of +2044G/A mutation carriage with specific phenotypes of CD and UC. The IL-13 gene +2044G/A mutation has no significant role in susceptibility to and phenotype of IBD.

    • 1 November 2006
      • Vol. 145  (11) , 844-9, 860

    [Infliximab in inflammatory bowel diseases--conference summary and suggested guidelines].

    by Iris Dotan, Yehuda Chowers, Daniel Rachmilewitz, Irit Chermesh, Alexandra Lavy, Eran Israeli, Amir Karban, Mitchell J Schwaber, Shmuel Odes, Rami Eliakim

    Infliximab, the monoclonal anti-tumor necrosis factor-alpha (TNF-alpha) antibodies preparation, is efficacious in the treatment of inflammatory bowel diseases. However, the optimal therapeutic approach is still under investigation. Reports on side effects and potential complications of infliximab therapy, as well as of other anti-TNF-alpha blocking agents are accumulating. Hence, the Israeli Gastroenterological Association had initiated a conference in order to discuss the frequent clinical issues that have arisen following the use of infliximab for the treatment of inflammatory bowel diseases. The aim was to report on the published clinical experience and problems regarding several practical aspects of the use of Infliximab, to suggest guidelines that are evidence-based and to discuss them with experienced IBD-oriented gastroenterologists. The subjects that were discussed include: (1) treatment protocols; (2) maintenance therapy in Crohn's disease; (3) prevention of infections and (4) therapeutic potential in ulcerative colitis. These topics reflect everyday issues that gastroenterologists deal with while treating inflammatory bowel disease patients. The manuscript summarizes the literature and evidence that were presented in the conference, the points raised at the discussions as well as guidelines suggested by work groups that were established for each subject. These guidelines may assist and direct the gastroenterologist treating inflammatory bowel disease patients with infliximab.

  • Polymorphisms in the TNF-α Promoter and Variability in the Granulomatous Response in Patients with Crohn's Disease

    by Ilan Dalal, Amir Karban, Eytan Wine, Rami Eliakim, Haim Shirin, Marcelo Fridlender, Ron Shaoul, Esther Leshinsky-Silver, Arie Levine

    Granulomas may be found in 30–70% of patients with Crohn's disease (CD). The etiology of granuloma formation in CD is presently unknown. Elevated levels of TNF-α are found within granuloma tissue, and are required to maintain granuloma formation in animal models. TNF-α production has been shown to influenced by TNF-α promoter polymorphisms. We hypothesized that heterogeneity for granulomas in CD might be influenced by the TNF-α promoter genotype. Patients with confirmed CD that had undergone full colonoscopy with multiple biopsies and/or surgical resection, served as the study group. One hundred healthy individuals served as a control population for genotyping. Patients and controls underwent genotyping for four TNF-α polymorphisms: 238G/A, 308 G/A,857 C/T, and 863 C/A. Inclusion and exclusion criteria were met in 155 patients (1–68 y). Polymorphisms in the TNF promoter were found in 16.6% (238G/A), 14.5% (308 G/A), 36.6% (857 C/T) and 30.7% (863G/A). No significant association was found for any of the individual polymorphisms with presence or absence of granulomas. In conclusion, we did not find an association between individual polymorphisms in the TNF-α promoter and presence of granulomas in CD. The reason for heterogeneity in granuloma formation in patients with CD remains elusive.


  • The Relation Between NOD2/CARD15 Mutations and the Prevalence and Phenotypic Heterogeneity of Crohn’s Disease: Lessons from the Israeli Arab Crohn’s Disease Cohort

    by Amir Karban, Oren Atia, Eran Leitersdorf, Azmi Shahbari, Wisam Sbeit, Zvi Ackerman, Rawia Mualem, Arie Levine, Shula Nesher, Rifaat Safadi, et al.

    The prevalence of Crohn's disease depends on geographic location and racial background. Arg702Trp, Gly908Arg, and Leu1007fsinsC mutations in the NOD2/CARD15 gene are associated with Crohn's disease in Caucasians. The mutation rate among Israeli Jewish patients is 27%-41%. The prevalence of Crohn's disease is much lower in the Israeli Arab compared to the Israeli Jewish population. We studied the NOD2/CARD15 mutation rate and disease phenotype (according to the Vienna classification) among the Israeli Arabs and compared them with those in an Israeli Jewish cohort. We recruited 66 Israeli Arab patients and 122 ethnically matched controls. Five patients (8.2%) and three controls (2.3%) carried one NOD2/CARD15 mutation. The phenotypic characteristics of the Arab and Jewish patients were very similar. We conclude that NOD2/CARD15 mutations do not contribute to Crohn's susceptibility in the Israeli Arab population and suggest that NOD2/CARD15 mutations have an important effect on Crohn's prevalence within a specific population but not on the phenotype.


  • P0134 PP EFFECT OF POLYMORPHISMS IN THE NOD2, TOLL LIKE RECEPTOR 4 AND TNF ALPHA PROMOTER GENES ON PEDIATRIC ONSET AND PHENOTYPE OF CROHN???S DISEASE: COMPARISON TO AN ADULT COHORT

    by Arie Levine, Amir A. Karban, Shimon S. Reif, Ron R. Shaoul, Rami Eliakim, Avi Pecht, Joram Wardi, Benjamin Yakir, Esther Leshinsky-Silver